Phathom Pharmaceuticals, Inc. PHAT Amortization expense related to capitalized debt issuance costs
Amortization expense related to capitalized debt issuance costs at other companies
Other financials
Where this comes from
Reported directly by Phathom Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:AmortizationOfFinancingCosts.
The official record: Phathom Pharmaceuticals, Inc.’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →
Ask your AI about Phathom Pharmaceuticals, Inc.'s amortization expense related to capitalized debt issuance costs.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Phathom Pharmaceuticals, Inc.'s amortization expense related to capitalized debt issuance costs?
- Phathom Pharmaceuticals, Inc. (PHAT) reported amortization expense related to capitalized debt issuance costs of $844K in Q1 2026.
- How has Phathom Pharmaceuticals, Inc.'s amortization expense related to capitalized debt issuance costs changed year-over-year?
- Phathom Pharmaceuticals, Inc.'s amortization expense related to capitalized debt issuance costs increased by 21.3% year-over-year, from $696K to $844K.
- What is the long-term trend for Phathom Pharmaceuticals, Inc.'s amortization expense related to capitalized debt issuance costs?
- Over 4 years (2021 to 2025), Phathom Pharmaceuticals, Inc.'s amortization expense related to capitalized debt issuance costs has grown at a -4.3% compound annual growth rate (CAGR), from $3.6M to $3.01M.